Showing results (101-110 of 175) with videos related to

Sort By:
Pageof 18
Oncoimmunology|August 21, 2019
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-lineAnna Kreutzman, Bhagwan Yadav, Tim H Brummendorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous LeukemiaSieghart Sopper, Satu Mustjoki, Deborah White, et al.
Blood Cancer Journal|February 25, 2022
Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemiaDipabarna Bhattacharya, Antonella Teramo, Vanessa Rebecca Gasparini, et al.
The Journal of Clinical Investigation|January 31, 2023
Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanomaJani Huuhtanen, Henna Kasanen, Katriina Peltola, et al.
European Journal of Haematology|August 21, 2021
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 studyHjalmar Flygt, Stina Söderlund, Jesper Stentoft, et al.
Haematologica|April 20, 2023
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cellsYannan Jia, Lina Han, Cassandra L Ramage, et al.
Cancer Research Communications|February 4, 2026
Functionally characterizing the renal cell carcinoma tumor immune microenvironment via patient-derived ex vivo modelsNeja Sirc, Johannes Smolander, Anita N Kumari, et al.
Nature Communications|February 7, 2024
Tracing back primed resistance in cancer via sister cellsJun Dai, Shuyu Zheng, Matías M Falco, et al.
Nature Communications|April 12, 2022
Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemiaJani Huuhtanen, Dipabarna Bhattacharya, Tapio Lönnberg, et al.
Journal for Immunotherapy of Cancer|August 7, 2021
Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoidsFiras Hamdan, Erkko Ylösmäki, Jacopo Chiaro, et al.
Pageof 18